Recent findings that heterozygous carriers of ATM are at increased risk of developing breast cancer with poor prognosis, and that the ATM gene is among the commonly aberrant genes in human sporadic breast cancer [20,21], suggest that our dual-targeting SP-1-303 HDAC inhibitor linked with an ATM activator may offer a novel approach for breast cancer treatment. Here, HDAC9 is linked to breast cancer.